Deqi Medical: Reached licensing cooperation with UST Biotech, with a total transaction amount close to $1.2 billion

2026-03-07 10:16:57

Abstract generation in progress

Recently, Deqi Pharmaceutical announced that the company has reached a global exclusive licensing agreement with UCB for ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases.

Under the licensing agreement, Deqi Pharmaceutical’s wholly owned subsidiary Antengene Biologics Limited and Deqi (Hangzhou) Biotech Co., Ltd. will grant UCB exclusive rights to further develop, manufacture, and commercialize ATG-201 worldwide.

Deqi Pharmaceutical will receive an upfront payment of $80 million and milestone payments in the near term, including $60 million upfront and an additional $20 million milestone payment upon meeting certain conditions.

Additionally, Deqi Pharmaceutical is eligible to receive up to approximately $1.1 billion in milestone payments based on successful development and commercialization, as well as tiered royalties based on future net sales.

ATG-201 is an investigational CD19/CD3 bispecific T-cell engager designed and developed to treat B-cell mediated autoimmune diseases. Deqi Pharmaceutical plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026, and after completing initial human (Phase I) clinical studies in these regions, will transfer subsequent clinical and related development work of ATG-201 to UCB.

(Deqi Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes